Kuangyn Yen | Gene Regulation and Epigenetics | Best Researcher Award

Dr. Kuangyn Yen | Gene Regulation and Epigenetics | Best Researcher Award

Chinese Academy of Medical Sciences and Peking Union Medical College | China 

Author Profile

Scopus 

Orcid ID

📘 KUANGYU YEN, PhD: PIONEER IN TRANSCRIPTION REGULATION AND CHROMATIN DYNAMICS

🎓 EARLY ACADEMIC PURSUITS

Kuangyu Yen's academic journey began at National Taiwan University, where he earned a Bachelor of Science in Horticulture (Molecular Biology Unit) in 1998. His passion for molecular biology led him to pursue advanced degrees at the University of Manchester, UK, where he completed both an MRes (2001) and a Ph.D. in Molecular Biology (2005). His doctoral research laid the foundation for his expertise in transcription regulation, setting the stage for his future research endeavors.

💼 PROFESSIONAL ENDEAVORS

Dr. Yen's professional career is marked by a blend of international experiences and prestigious appointments:

  • Chinese Academy of Medical Sciences & Peking Union Medical College (2022-present): Researcher.
  • Southern Medical University (2014-2022): Professor, where he contributed significantly to the academic and research community in Guangzhou, China.
  • Pennsylvania State University (2008-2014): Post-doctoral fellow and later Research Assistant Professor, expanding his expertise in transcription regulation and chromatin dynamics.
  • University of Washington (2005-2007): Post-doctoral fellow, further deepening his understanding of molecular biology at the intersection of chromatin and transcription.
  • National Taiwan University (1998-2000): Research Assistant, where his scientific curiosity began to flourish.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON GENE REGULATION AND EPIGENETICS

Dr. Yen's research focus is on transcription regulation and its influence on cell fate determination, particularly through chromatin dynamics. His innovative use of bioinformatic tools, CRISPR/Cas9-engineered depletion, and biochemical reconstitution has made him a leader in understanding how chromatin regulates transcription in a spatiotemporal manner. His research has significant implications for disease diagnosis and treatment, especially in preventing precancerous cells from progressing into cancer cells. One of his notable contributions is the development of a two-tipping point model, which helps explain how cell fate transitions. This model has potential applications in both basic research and clinical practice, offering insights into the molecular mechanisms of various diseases.

🌍 IMPACT AND INFLUENCE

Dr. Yen’s work has been internationally recognized, and he has secured multiple high-profile grants and awards, such as the Thousand Youth Talents Award and the Outstanding Youth Award. His research has attracted funding from the National Natural Science Foundation of China, the National Key Research and Development Program of China, and international collaborations such as the France-China Joint Research Projects Program. His influence extends to key speaking engagements and workshops in the field of epigenetics and hematopoiesis at global institutions, including John Hopkins University.

📊 ACADEMIC CITATIONS

With several publications to his name, Dr. Yen’s work is well-cited in the scientific community, reinforcing his status as an influential researcher in molecular biology. His contributions to understanding transcription regulation and chromatin dynamics continue to resonate, particularly in the areas of epigenetics and hematopoiesis.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Kuangyu Yen’s legacy will likely center on his pioneering research into how chromatin structure affects transcriptional regulation and cell fate transitions. His use of cutting-edge tools like CRISPR/Cas9 and bioinformatics has laid the groundwork for future advancements in cancer prevention and molecular diagnostics. Moving forward, Dr. Yen’s ongoing research at the Chinese Academy of Medical Sciences is poised to further influence how scientists understand and manipulate transcription regulation. His editorial role at Communication Biology (2024-2026) and other professional activities suggest that his contributions to the field are far from over.

🚀 AWARDS AND PROFESSIONAL RECOGNITION

  • National Natural Science Foundation of China: Multiple grants for outstanding research, totaling over 500,000 USD.
  • Thousand Youth Talents Award: A prestigious recognition with funding of 0.67 million USD.
  • Numerous invited talks at top-tier institutions and international conferences.

Kuangyu Yen’s continuous dedication to his research and the academic community positions him as a transformative figure in molecular biology, with future contributions set to further shape the field.

📅 FUTURE HIGHLIGHTS

Dr. Yen’s ongoing projects and his active engagement with the scientific community, including participation in international editorial boards and professional panels, indicate that his work will continue to shape the future of molecular biology research for years to come.

📑NOTABLE PUBLICATIONS 

"RUNX1 Upregulates CENPE to Promote Leukemic Cell Proliferation" 

  • Authors: Liu, S., Yang, J., Sun, G., Yen, K., & Lu, T. (2021).
  • Journal: Molecular Biosciences
  • Year: 2021

"Chemical screening reveals Ronidazole is a superior prodrug to Metronidazole for nitroreductase-induced cell ablation system in zebrafish larvae" 

  • Authors: Lai, S., Kumari, A., Liu, J., Yen, K., & Xu, J.
  • Journal: Genetics and Genomics
  • Year: 2021

"Comprehensive understanding of Tn5 insertion preference improves transcription regulatory element identification"

  • Authors: Zhang, H., Lu, T., Liu, S., Chen, F., & Yen, K.
  • Journal: NAR Genomics and Bioinformatics
  • Year: 2021

"Functional Verification of Novel ELMO1 Variants by Live Imaging in Zebrafish"

  • Authors: Xue, R., Wang, Y., Wang, T., Liu, Q., & Xu, J.
  • Journal: Frontiers in Cell and Developmental Biology
  • Year: 2021

"SPI1-KLF1/LYL1 axis regulates lineage commitment during endothelial-to-hematopoietic transition from human pluripotent stem cells"

  • Authors: Qu, K., Mo, S., Huang, J., Shen, J., & Yen, K.
  • Journal: iScience
  • Year: 2024

Ning Li | Gene Regulations | Best Researcher Award

Dr. Ning Li | Gene Regulations | Best Researcher Award

Tianjin University | China

Author Profile

Scopus

Li Ning, Ph.D. 🧬

Lecturer, School of Disaster and Emergency Medicine, Faculty of Medicine

Research Areas :🧠

  • Molecular mechanisms of traumatic injury
  • Immunotherapy
  • Mechanobiology

📧 Email: lining620@tju.edu.cn

Brief Introduction:

Dr. Li Ning received her Ph.D. from Nankai University, China, in 2019. Since then, she has been a dedicated lecturer at Tianjin University, where she also supervises master's students. Her research delves into the pathogenic mechanisms of trauma, cell death in trauma-related diseases, immunotherapy, and biomechanics within disaster medicine. Dr. Ning has led numerous national, provincial, and university-level research projects, with her work published in esteemed journals like Nucleic Acids Research, Military Medical Research, Trends in Pharmacological Sciences, Cell Death & Discovery, and Pharmacological Research.

Educational Background 🎓

  • 2008.09 - 2012.07: Bachelor's in Bioscience and Biotechnology, Shenyang Agricultural University
  • 2012.09 - 2015.07: Master's in Medicine, Nankai University
  • 2015.09 - 2018.12: Ph.D. in Pharmacy, Nankai University

Professional Experience 💼

  • 2019.05 - Present: Lecturer, School of Disaster and Emergency Medicine, Faculty of Medicine, Tianjin University

Academic Achievements:

Dr. Li Ning has an impressive list of published research papers, several of which highlight her contributions to the understanding of cell death mechanisms and potential therapeutic targets for trauma management. Additionally, she holds multiple patents, including innovations in nucleic acid detection and crush injury modeling equipment.

Fellowships & Honors 🏆

  • Excellent Master's Thesis, Nankai University (2015)
  • Teaching and Educating Excellence Award, Tianjin University (2022)
  • Scientific Research Rookie Award, Tianjin University (2022)
  • Outstanding Mentor, Tianjin University (2023)
  • Multiple awards for outstanding contributions and excellence in teaching from Tianjin University (2022-2024)

Dr. Ning continues to contribute significantly to the fields of disaster and emergency medicine through her research and teaching.

Journal Publications 📚

  • Nucleic Acids Research
    • Li Ning might have contributed research on the molecular mechanisms of traumatic injury, possibly focusing on DNA damage and repair mechanisms or gene expression changes post-injury.
  • Military Medical Research
    • Research related to trauma, particularly in military settings, could include studies on immunotherapy and the impact of cell death on traumatic injuries, as well as advances in medical biomechanics.
  • Trends in Pharmacological Sciences
    • Likely publications could discuss cutting-edge approaches in immunotherapy or pharmacological interventions targeting trauma-induced pathogenesis.
  • Cell Death & Discovery
    • Studies on the role of cell death in trauma-related diseases, focusing on molecular pathways and therapeutic targets.
  • Pharmacological Research
    • Research papers could include findings on drug interventions for trauma-induced pathologies, including immunotherapeutic strategies and their mechanobiological implications.

Notable Publications 📑

"Ferroptosis in acute kidney injury following crush syndrome: A novel target for treatment" 

  • Authors: Qiao, O., Wang, X., Wang, Y., Li, N., Gong, Y.
  • Journal: Journal of Advanced Research
  • Year: 2023

"Biotherapy of experimental acute kidney injury: emerging novel therapeutic strategies" 

  • Authors: Li, N., Han, L., Wang, X., Zhang, L., Gong, Y.
  • Journal: Translational Research
  • Year: 2023

"Delayed step-by-step decompression with DSF alleviates skeletal muscle crush injury by inhibiting NLRP3/CASP-1/GSDMD pathway "

  • Authors: Li, N., Wang, X., Wang, Y., Fan, H., Gong, Y.
  • Journal: Cell Death Discovery
  • Year: 2023

"Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation"

  • Authors: Yu, J., Du, Y., Liu, C., Wang, Y., Qin, J.
  • Journal: Life Sciences
  • Year: 2024

"Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation"

  • Authors: Xie, Y., Shan, M., Yu, J., Lan, L., Wang, Y.
  • Journal: Cancer Science
  • Year: 2024